Updated:
BullFrog AI Holdings, Inc.
BullFrog AI Holdings, Inc., listed on the Nasdaq in 2022, has not disclosed its founding year or founding principals publicly.
BullFrog AI Holdings, Inc.
BullFrog AI Holdings, Inc., listed on the Nasdaq in 2022, has not disclosed its founding year or founding principals publicly. The company's stated focus is on using artificial intelligence to analyze clinical and preclinical data for pharmaceutical and biotechnology partners, particularly in oncology and neurology. The firm's strategy revolves around a platform called bfLeap™, which applies machine learning to identify biomarkers and predict drug responses. BullFrog AI has not publicly disclosed portfolio companies or deployment figures and appears to operate as a publicly traded entity rather than a family office. Its geographic footprint is unclear from available records. No team size, additional offices, or adjacent vehicles have been confirmed. The most recent notable operational event was its Nasdaq listing in 2022 (per public filings, 2022). BullFrog AI's structural differentiator is its public listing, making it a rare publicly traded asset manager focused on AI-driven drug development. However, its lack of disclosed AUM, deployment, or principals limits visibility into its actual investment activities.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
What is BullFrog AI's business model?
BullFrog AI describes itself as an AI-powered drug development company that uses its bfLeap™ platform to analyze clinical data for pharmaceutical partners. It does not appear to manage third-party capital or operate as a family office.
Is BullFrog AI a family office?
No. BullFrog AI Holdings, Inc. is a publicly traded company listed on the Nasdaq. It does not present itself as a single- or multi-family office.
Who are the principals leading BullFrog AI?
Public records do not clearly identify named principals or leadership beyond standard corporate filings. The firm's website and public disclosures have not highlighted investment professionals.
What sectors does BullFrog AI focus on?
The firm targets the healthcare and life sciences sectors, with emphasis on oncology and neurology. It applies machine learning to clinical trial data to improve drug success rates.
Has BullFrog AI deployed capital in any known companies?
No. The firm has not publicly disclosed any portfolio companies, co-investments, or fund commitments. Its activity appears concentrated on service-based partnerships with drug developers.
When was BullFrog AI founded and where is it headquartered?
The firm's founding year is not publicly available. It became a public company in 2022, but its headquarters location is not confirmed. Public filings and websites are sparse.
Does BullFrog AI accept external investments?
As a publicly traded entity, any investor can purchase shares of BullFrog AI Holdings on the Nasdaq. However, it does not appear to raise dedicated investment funds from institutions or allocators.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: